MX2020013927A - Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo. - Google Patents

Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.

Info

Publication number
MX2020013927A
MX2020013927A MX2020013927A MX2020013927A MX2020013927A MX 2020013927 A MX2020013927 A MX 2020013927A MX 2020013927 A MX2020013927 A MX 2020013927A MX 2020013927 A MX2020013927 A MX 2020013927A MX 2020013927 A MX2020013927 A MX 2020013927A
Authority
MX
Mexico
Prior art keywords
sub
cognitive impairment
compositions
containing gaba
treating
Prior art date
Application number
MX2020013927A
Other languages
English (en)
Inventor
Belew Mekonnen
John A Butera
Jianxing Huang
Robert Jason Herr
Hemantbhai Patel
Qin Jiang
Nicholas James Mayhew
Emily Elizabeth Freeman
Original Assignee
Agenebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenebio Inc filed Critical Agenebio Inc
Publication of MX2020013927A publication Critical patent/MX2020013927A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a derivados de benzodiazepina, a composiciones que comprenden cantidades terapéuticamente eficaces de esos derivados y a métodos para usar esos derivados o composiciones en el tratamiento del deterioro cognitivo asociado con trastornos del SNC. También se relaciona con el uso de un agonista del receptor GABAA que contiene a5 (por ejemplo, un modulador alostérico positivo del receptor GABAA que contiene a5) en el tratamiento del deterioro cognitivo asociado con trastornos del SNC en un sujeto que lo necesite o esté en riesgo, incluyendo deterioro cognitivo relacionado con la edad, deterioro cognitivo leve (DCL), DCL amnésico, deterioro de la memoria asociado a la edad, declive cognitivo relacionado con la edad, demencia, enfermedad de Alzheimer (EA), EA prodrómica, TEPT, esquizofrenia, trastorno bipolar, ELA, deterioro cognitivo relacionado con la terapia del cáncer, retraso mental, enfermedad de Parkinson, trastornos del espectro autista, trastorno X frágil, síndrome de Rett, comportamiento compulsivo y adicción a sustancias. También se refiere al uso de un agonista del receptor GABAA que contiene a5 (por ejemplo, un modulador alostérico positivo del receptor GABAA que contiene a5) en el tratamiento de cánceres cerebrales (incluidos tumores cerebrales, por ejemplo, meduloblastomas), y el deterioro cognitivo asociado con el mismo.
MX2020013927A 2018-06-19 2019-06-19 Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo. MX2020013927A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687195P 2018-06-19 2018-06-19
PCT/US2019/038038 WO2019246300A1 (en) 2018-06-19 2019-06-19 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Publications (1)

Publication Number Publication Date
MX2020013927A true MX2020013927A (es) 2021-03-02

Family

ID=68984202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013927A MX2020013927A (es) 2018-06-19 2019-06-19 Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.

Country Status (11)

Country Link
US (2) US11414425B2 (es)
EP (1) EP3810611A4 (es)
JP (1) JP7514534B2 (es)
CN (1) CN112601749B (es)
AU (1) AU2019288382B2 (es)
BR (1) BR112020026062B1 (es)
CA (1) CA3104478A1 (es)
EA (1) EA202190076A1 (es)
IL (1) IL279530A (es)
MX (1) MX2020013927A (es)
WO (1) WO2019246300A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934553C (en) 2013-12-20 2023-10-31 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
IL256354B (en) 2015-06-19 2022-09-01 Agenebio Inc History of benzodiazepines, preparations and their use for the treatment of cognitive impairment
US11505555B2 (en) * 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
IL294031A (en) * 2019-12-19 2022-08-01 Agenebio Inc History of benzodiazepines, preparations and methods for the treatment of cognitive impairment
JP2023534189A (ja) * 2020-07-10 2023-08-08 エージンバイオ， インコーポレイテッド Ｇａｂａａアルファ５アゴニストおよびｓｖ２ａ阻害剤の組合せ物ならびに認知障害の処置において使用する方法
CN116457019A (zh) * 2020-07-10 2023-07-18 艾吉因生物股份有限公司 GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法
WO2024023268A1 (en) 2022-07-29 2024-02-01 F. Hoffmann-La Roche Ag Characterisation of neurological dysfunction
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
ATE94384T1 (de) 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
EP0402644B1 (en) 1989-05-19 1995-08-16 Hoechst-Roussel Pharmaceuticals Incorporated N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
ES2131506T3 (es) 1990-09-21 1999-08-01 Rohm & Haas Dihidropiridacinonas y piridacinonas como fungicidas.
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
EP0781768B1 (en) 1991-05-24 2001-11-21 E.I. Du Pont De Nemours And Company Arthropodicidal anilides
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
TW201311B (es) 1991-06-17 1993-03-01 Hoffmann La Roche
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
CA2182981C (en) 1994-03-02 2006-10-17 Leonardus Petrus Carla Delbressine Sublingual or buccal pharmaceutical composition
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
AU1041599A (en) 1997-11-13 1999-06-07 Jose Luis Castro Pineiro Therapeutic uses of triazolo-pyridazine derivatives
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1129094A2 (en) 1998-11-12 2001-09-05 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
AU2825600A (en) 1999-03-03 2000-09-21 Eisai Co. Ltd. Fluorides of 4-substituted piperidine derivatives
GB9911803D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911804D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911802D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9929569D0 (en) 1999-12-14 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
KR20030076717A (ko) 2001-03-01 2003-09-26 화이자 프로덕츠 인크. 인지 장애의 치료를 위한 니코틴 수용체 부분 아고니스트,에스트로겐, 선택적 에스트로겐 조정자 또는 비타민 ｅ와함께, ｇａｂａａ 역아고니스트의 용도
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
US20050071088A1 (en) 2001-08-13 2005-03-31 Landfield Philip W Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
CN1642547A (zh) 2002-01-16 2005-07-20 恩多制药公司 治疗中枢神经系统障碍的药物组合物和方法
EP1532120B1 (en) 2002-08-13 2009-01-14 MERCK SHARP & DOHME LTD. Phenylpyridazine derivatives as ligands for gaba receptors
GB0218876D0 (en) 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
EA008863B1 (ru) 2002-10-24 2007-08-31 Мерц Фарма Гмбх Унд Ко. Кгаа Комбинированная терапия с использованием производных 1-аминоциклогексана и ингибиторов ацетилхолинэстеразы
CN101249090A (zh) 2002-11-22 2008-08-27 约翰斯·霍普金斯大学 治疗认知功能障碍的靶位
US20050113458A1 (en) 2003-10-22 2005-05-26 Forest Laboratories, Inc. Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
US20060079582A1 (en) 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
EP1809297B1 (en) 2004-10-12 2008-07-30 F. Hoffmann-Roche AG Imidazo[1,5a]triazolo[1,5d]benzodiazepine derivatives for the treatment of cognitive disorders
MX2007004639A (es) 2004-10-20 2007-06-08 Hoffmann La Roche Derivados de imidazo-benzodiazepina.
AU2005299031B2 (en) 2004-10-20 2011-11-10 F. Hoffmann-La Roche Ag Halogen substituted benzodiazepine derivatives
CA2590333C (en) 2004-12-14 2013-01-08 F. Hoffmann-La Roche Ag Tetracyclic imidazo-benzodiazepines as gaba receptors modulators
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EP1888594A2 (en) 2005-05-16 2008-02-20 Wisys Technology Foundation, Inc. Gabaergic agents to treat memory deficits
EP1924712B1 (en) 2005-08-03 2018-10-03 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
JP4885967B2 (ja) 2005-10-11 2012-02-29 エフ．ホフマン−ラ ロシュ アーゲー イミダゾベンゾジアゼピン誘導体
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
EP2318005B1 (en) 2008-08-01 2017-11-01 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US20110136762A1 (en) 2008-09-24 2011-06-09 E.I. Du Pont De Nemours And Company Fungicidal pyridazines
AU2009295586B2 (en) 2008-09-25 2014-01-09 Vive Nano, Inc. Methods to produce polymer nanoparticles and formulations of active ingredients
US8344028B2 (en) 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
JP2013516497A (ja) 2010-01-11 2013-05-13 ミスリィディオン，インク． 認知増強のための化合物と組成物、製造方法、および治療方法
SG189248A1 (en) 2010-11-05 2013-06-28 Hoffmann La Roche Use of active pharmaceutical compounds for the treatment of central nervous system conditions
BR112013012072A2 (pt) 2010-11-15 2016-08-16 Agenebio Inc derivados, composições de benzodiazepina e métodos para o tratamento de danos cognitivos
JP5916746B2 (ja) 2010-11-15 2016-05-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのピリダジン誘導体、組成物、および方法
WO2012161133A1 (ja) 2011-05-20 2012-11-29 日産化学工業株式会社 置換ピリダジン化合物及び農園芸用殺菌剤
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2884566A1 (en) 2012-09-10 2014-03-13 Matthew R. Lewin Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
CA2934553C (en) 2013-12-20 2023-10-31 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
IL256354B (en) 2015-06-19 2022-09-01 Agenebio Inc History of benzodiazepines, preparations and their use for the treatment of cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN108567787A (zh) * 2017-03-10 2018-09-25 辛衍雪 一种治疗慢性阻塞性肺病的药物组合物
CN108567786A (zh) * 2017-03-10 2018-09-25 陈洪国 一种治疗溃疡性结肠炎的药物组合物

Also Published As

Publication number Publication date
BR112020026062B1 (pt) 2023-04-04
US11414425B2 (en) 2022-08-16
JP7514534B2 (ja) 2024-07-11
JP2021528427A (ja) 2021-10-21
CN112601749A (zh) 2021-04-02
EP3810611A4 (en) 2022-03-30
AU2019288382A1 (en) 2021-02-11
IL279530A (en) 2021-01-31
WO2019246300A1 (en) 2019-12-26
EP3810611A1 (en) 2021-04-28
CN112601749B (zh) 2024-03-26
US20230107032A1 (en) 2023-04-06
CA3104478A1 (en) 2019-12-26
AU2019288382B2 (en) 2024-07-25
EA202190076A1 (ru) 2021-09-22
BR112020026062A2 (pt) 2021-03-23
US20200048268A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
MX2020013927A (es) Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
MX2019007338A (es) Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo.
MX2022007725A (es) Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo.
MX2016007808A (es) Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo.
MX2020013374A (es) Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo.
EA201390710A1 (ru) Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения
GEP20207149B (en) Allosteric modulators of nicotinic acetylcholine receptors
GEP20227446B (en) New catecholamine prodrugs for use in treatment of parkinson's disease
AU2019268069A1 (en) Methods and compositions for improving cognitive function
EA201390712A1 (ru) Производные пиридазина, композиции и способы лечения когнитивного нарушения
MX2023000405A (es) Combinaciones de agonistas del receptor a del acido gamma aminobutirico (gabaa) alfa 5 e inhibidores de la glicoproteina de vesicula sinaptica 2a (sv2a) y metodos de uso en el tratamiento del deterioro cognitivo.
PH12020551779A1 (en) Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
MA43313B1 (fr) Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
SA520420382B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1
MX2021007142A (es) Compuestos organicos.
Fujioka et al. Clinical presentation of a patient with SLC20A2 and THAP1 deletions: differential diagnosis of oromandibular dystonia
EA201691290A1 (ru) Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения
FI3541784T3 (fi) Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina
PH12019550251A1 (en) HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS
MX2024005979A (es) Compuestos dirigidos a pmp22 para el tratamiento de la enfermedad de charcot-marie-tooth.
EA201892113A1 (ru) Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов
Kar et al. Impact of High Dose Lorazepam on Seizure Threshold in Catatonia: Experience from a Case Study
Park et al. Nemaline Myopathy Presenting as Adult-onset Distal Myopathy